Phase II Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) Post Azacytidine (AZA) Failure

Trial Profile

Phase II Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) Post Azacytidine (AZA) Failure

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Decitabine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2011 Actual end date (1 Nov 2008) added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 10 Nov 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top